172 related articles for article (PubMed ID: 35227644)
1. Metformin increases the radiosensitivity of non-small cell lung cancer cells by destabilizing NRF2.
Sun X; Dong M; Gao Y; Wang Y; Du L; Liu Y; Wang Q; Ji K; He N; Wang J; Zhang M; Gu Y; Song H; Zhai H; Feng L; Xu C; Liu Q
Biochem Pharmacol; 2022 May; 199():114981. PubMed ID: 35227644
[TBL] [Abstract][Full Text] [Related]
2.
Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
[TBL] [Abstract][Full Text] [Related]
3. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses.
Lee S; Lim MJ; Kim MH; Yu CH; Yun YS; Ahn J; Song JY
Free Radic Biol Med; 2012 Aug; 53(4):807-16. PubMed ID: 22684019
[TBL] [Abstract][Full Text] [Related]
4. PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.
Ji L; Zhang R; Chen J; Xue Q; Moghal N; Tsao MS
Sci Rep; 2019 Aug; 9(1):12437. PubMed ID: 31455821
[TBL] [Abstract][Full Text] [Related]
5. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
8. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.
Wang Q; Ma J; Lu Y; Zhang S; Huang J; Chen J; Bei JX; Yang K; Wu G; Huang K; Chen J; Xu S
Oncogene; 2017 Sep; 36(37):5321-5330. PubMed ID: 28534518
[TBL] [Abstract][Full Text] [Related]
9. The EGR1/miR-139/NRF2 axis orchestrates radiosensitivity of non-small-cell lung cancer via ferroptosis.
Zhang L; Xu Y; Cheng Z; Zhao J; Wang M; Sun Y; Mi Z; Yuan Z; Wu Z
Cancer Lett; 2024 Jul; 595():217000. PubMed ID: 38821254
[TBL] [Abstract][Full Text] [Related]
10. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
[TBL] [Abstract][Full Text] [Related]
11. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
[TBL] [Abstract][Full Text] [Related]
12. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
Singh A; Boldin-Adamsky S; Thimmulappa RK; Rath SK; Ashush H; Coulter J; Blackford A; Goodman SN; Bunz F; Watson WH; Gabrielson E; Feinstein E; Biswal S
Cancer Res; 2008 Oct; 68(19):7975-84. PubMed ID: 18829555
[TBL] [Abstract][Full Text] [Related]
13. PPIA dictates NRF2 stability to promote lung cancer progression.
Lu W; Cui J; Wang W; Hu Q; Xue Y; Liu X; Gong T; Lu Y; Ma H; Yang X; Feng B; Wang Q; Zhang N; Xu Y; Liu M; Nussinov R; Cheng F; Ji H; Huang J
Nat Commun; 2024 Jun; 15(1):4703. PubMed ID: 38830868
[TBL] [Abstract][Full Text] [Related]
14. Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities.
Riaz MA; Sak A; Erol YB; Groneberg M; Thomale J; Stuschke M
Sci Rep; 2019 Feb; 9(1):1282. PubMed ID: 30718758
[TBL] [Abstract][Full Text] [Related]
15. Metformin Sensitizes Non-small Cell Lung Cancer Cells to an Epigallocatechin-3-Gallate (EGCG) Treatment by Suppressing the Nrf2/HO-1 Signaling Pathway.
Yu C; Jiao Y; Xue J; Zhang Q; Yang H; Xing L; Chen G; Wu J; Zhang S; Zhu W; Cao J
Int J Biol Sci; 2017; 13(12):1560-1569. PubMed ID: 29230104
[TBL] [Abstract][Full Text] [Related]
16. Bazedoxifene-induced ROS promote mitochondrial dysfunction and enhance osimertinib sensitivity by inhibiting the p-STAT3/SOCS3 and KEAP1/NRF2 pathways in non-small cell lung cancer.
Meng Y; Lin W; Wang N; Wei X; Huang Q; Liao Y
Free Radic Biol Med; 2023 Feb; 196():65-80. PubMed ID: 36646328
[TBL] [Abstract][Full Text] [Related]
17. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
[TBL] [Abstract][Full Text] [Related]
18. PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting Nrf2 protein degradation.
Xu P; Jiang L; Yang Y; Wu M; Liu B; Shi Y; Shen Q; Jiang X; He Y; Cheng D; Xiong Q; Yang Z; Duan L; Lin J; Zhao S; Shi P; Yang C; Chen Y
Theranostics; 2020; 10(8):3767-3778. PubMed ID: 32206121
[No Abstract] [Full Text] [Related]
19. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.
Shen X; Zhao Y; Liu G; Zhou HL; Fan J; Zhang L; Li YL; Wang Y; Liang J; Xu ZX
Life Sci; 2020 Sep; 256():117923. PubMed ID: 32522567
[TBL] [Abstract][Full Text] [Related]
20. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors.
Singh A; Venkannagari S; Oh KH; Zhang YQ; Rohde JM; Liu L; Nimmagadda S; Sudini K; Brimacombe KR; Gajghate S; Ma J; Wang A; Xu X; Shahane SA; Xia M; Woo J; Mensah GA; Wang Z; Ferrer M; Gabrielson E; Li Z; Rastinejad F; Shen M; Boxer MB; Biswal S
ACS Chem Biol; 2016 Nov; 11(11):3214-3225. PubMed ID: 27552339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
